Cannell & Spears’s Integra LifeSciences IART Stock Holding History

Cannell & Spears’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-116,630	Closed	-$2.56M	–	406
2025 Q1	$2.56M	Sell	116,630 -40,116	-26%	-$943K	0.06%	174
2024 Q4	$3.55M	Buy	+156,746	New	+$3.42M	0.07%	151
2024 Q3	–	Sell	-240,876	Closed	-$7.02M	–	411
2024 Q2	$7.02M	Buy	240,876 +220,588	+1,087%	+$6.54M	0.15%	108
2024 Q1	$719K	Buy	+20,288	New	+$811K	0.01%	249
2021 Q4	–	Sell	-4,785	Closed	-$328K	–	239
2021 Q3	$328K	Hold	4,785	–	–	0.02%	180
2021 Q2	$327K	Buy	4,785 +1,159	+32%	+$82K	0.02%	188
2021 Q1	$251K	Sell	3,626 -254	-7%	-$17.2K	0.02%	202
2020 Q4	$252K	Buy	+3,880	New	+$209K	0.02%	199
2020 Q3	–	Sell	-4,287	Closed	-$201K	–	236
2020 Q2	$201K	Buy	+4,287	New	+$211K	0.02%	209

Other funds holding IART

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCMI

Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cannell & Spears's IART Position: Q2 2025 in Review

Cannell & Spears sold out of Integra LifeSciences (IART) in Q2 2025, closing a stake of 116,630 shares — an estimated $2.56M sold.

Cannell & Spears first reported a position in IART in Q2 2020 and held it in 9 quarters. The position peaked at $7.02M in Q2 2024. 208 funds tracked by Wall St. Rank hold IART as of Q2 2025.

Cannell & Spears reported no remaining Integra LifeSciences position as of Q2 2025 after selling out during the quarter.
Cannell & Spears sold 116,630 Integra LifeSciences shares in Q2 2025, an estimated $2.56M.
Cannell & Spears first reported a position in Integra LifeSciences in Q2 2020 and held it in 9 quarters.
Cannell & Spears's Integra LifeSciences position peaked at $7.02M in Q2 2024.
208 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2025.

Based on Cannell & Spears's 13F filing for Q2 2025, filed 14 Aug 2025.